Obstructive Sleep Apnea (OSAS)
Conditions
Keywords
Obstruktive sleep apnea, sarcopenia, respiratory muscle
Brief summary
OSAS is a disease characterized by repeated interruptions and restarts of breathing during sleep. Respiratory muscle sarcopenia is a condition in which the muscle strength of the diaphragm and other respiratory auxiliary muscles decreases, resulting in a decrease in breathing effort. Decreased respiratory effort is an important indicator of OSAS. Age, presence of chronic disease, and obesity increase the presence and severity of respiratory sarcopenia. If OSAS is left untreated, it leads to cardiovascular diseases, dementia, Alzheimer's and even death in early adulthood. In recent years, studies have shown that continuous positive airway pressure (CPAP), as well as healthy behavior development, preventive health and exercise measures, are important in the management of these diseases. There is no research in the literature on the evaluation of respiratory muscle sarcopenia in OSAS patients. This study aims to evaluate respiratory muscle sarcopenia in OSAS based on a concrete value reflecting respiratory muscle strength and/or volume.
Detailed description
In the study, respiratory muscle sarcopenia will be evaluated in OSAS patients. It will be evaluated whether the expiratory pressure value, peek flow meter value and 6-minute walking distance are predictors of respiratory sarcopenia for OSAS.
Interventions
None listed
Sponsors
Tarsus University
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosed with normal-mild-medium-severe OSAS * 18 years and above * Turkish speaking patients will be included.
Exclusion criteria
* Pregnancy, * Latent autoimmune diabetes, * Chronic renal failure, * Active or serious infections, * Liver failure, * Recent major cardiovascular events, * Unstable angina, heart failure (NYHA III-IV), * Patients with neurological or musculoskeletal disorders that create limitations in walking and performing tests
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Respiratory function test | 1 year | To evaluate pulmonary functions(FEV1/FVC ve FEV1 ), it will be measured in a sitting position with a Spirolab III brand spirometer according to ATS/European Respiratory Society (ERS) criteria. |
| Anthropometric measurement | 1 year | Waist circumference, hip circumference will be measured, waist-hip ratio will be calculated. |
| BOdy mass measurement | 1 year | Body weight,fat-free mass (FFM) and appendicular skeletal muscle mass (ASMM) and skeletal muscle mass expressed in kilograms will be measured by bioelectrical impedance. |
| Hand Grip strength | 1 year | Jamar hand dynamometer, which is recommended by the American Association of Hand Therapists (AETD) and has been found to have high validity and reliability in many studies and is therefore considered the gold standard, will be used to measure hand grip strength. |
| Walking speed | 1 year | Walking speed will be measured with the 4 Meter Walking Speed Test (4MYHT). |
| Respiratory muscle strength: | 1 year | Respiratory muscle strength will be evaluated with a portable, electronic mouth pressure measurement device. |
| Expiratory flow rate | 1 year | Peak expiratory flow (PEF), also called peak expiratory flow rate (PEFR) and peak flow measurement, will be measured with a PEFmeter (MSA 100 PEFmeter), a small, hand-held device used to monitor a person's ability to breathe air. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Functional capacity | 1 year | Functional exercise capacity will be evaluated with the 6-minute walk test (6MWT) |
Countries
Turkey (Türkiye)
Outcome results
None listed